Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk AML (MYELOMATCH SubStudy)
NCT05554393Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Measurable residual disease (MRD) undetectable complete remission (CR). Started Sep 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05554393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554393.